Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.

about

Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series

P2860

Q58732728-0D9FCCBD-6CF8-41AA-B241-1388BFE0349B

P2860

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.

Item

http://www.wikidata.org/entity/Q55114350

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immune Monitoring of Cancer Pa ...... D-1/PD-L1 Inhibitor Treatment.

@en

Immune Monitoring of Cancer Pa ...... D-1/PD-L1 Inhibitor Treatment.

@nl

type

Item

label

Immune Monitoring of Cancer Pa ...... D-1/PD-L1 Inhibitor Treatment.

@en

Immune Monitoring of Cancer Pa ...... D-1/PD-L1 Inhibitor Treatment.

@nl

prefLabel

Immune Monitoring of Cancer Pa ...... D-1/PD-L1 Inhibitor Treatment.

@en

Immune Monitoring of Cancer Pa ...... D-1/PD-L1 Inhibitor Treatment.

@nl

P1476

Immune Monitoring of Cancer Pa ...... D-1/PD-L1 Inhibitor Treatment.

@en

P2093

Antje Tunger

http://www.w3.org/2001/XMLSchema#string

Friedegund Meier

http://www.w3.org/2001/XMLSchema#string

Marc Schmitz

http://www.w3.org/2001/XMLSchema#string

Maximilian Kießler

http://www.w3.org/2001/XMLSchema#string

Rebekka Wehner

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

Molecular and cellular insights into T cell exhaustion

Immune Checkpoint Blockade in Cancer Therapy

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

P31

scholarly article

P356

10.3390/BIOMEDICINES6010026

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael Bachmann

Achim Temme

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29494517

http://www.w3.org/2001/XMLSchema#string

P932

5874683

http://www.w3.org/2001/XMLSchema#string

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.

about

P2860

P2860

Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932